The timeline for valuation up ticks are visible above and the next reset valuation event when Aegros raises funding is expected to be the Pre IPO raise when Aegros is generating revenue.
The valuation for this could be over $5-$8 per share or $500m - $800m with revenue and proven commercialisation of significant value.
An IPO/Trade Sale could potentially happen in 18 - 24 months when Covimmune® is a registered product with the TGA.
